CHAPEL HILL, N.C.--(BUSINESS WIRE)--Pharma Initiatives, the premier management consultancy dedicated to growth, innovation, and change management strategy in clinical research and medical affairs, today announced the addition of Mark Shapiro as Partner. He brings two decades of experience in the pharmaceutical, CRO and biotech sectors. Shapiro is widely recognized as an expert on the business of clinical research and is frequently quoted in the press, including Outsourcing Pharma, PharmaVoice, and CenterWatch. His focus at Pharma Initiatives will be growth and innovation strategies in clinical research, drug development, and medical affairs.
Prior to joining Pharma Initiatives, Mr. Shapiro was SVP, Operations at a global CRO, where he was responsible for a team of about 500 drug development professionals in 30 countries, and a portfolio of more than 100 active clinical trials. He was previously a management consultant in the Clinical Development and Medical Affairs consulting practice at Campbell Alliance, a firm specializing in pharmaceutical research and development process improvement, where his clients included many of the top 50-pharmaceutical and biotechnology companies.
During his career, Shapiro led the operations for a pediatric drug safety research network coordinating center that conducted clinical, pharmacogenomic, and psychometric research studies. He has published many peer-reviewed articles on clinical trial design, methods, and the impact of regulatory changes on research. He is an author of the PAERS, the Pediatric Adverse Events Rating Scale, which is frequently used in pediatric drug development.
Shapiro received his MBA from Duke University and completed master’s and Doctoral work in pharmacology and biomolecular pharmacology, respectively, at the Boston University School of Medicine. He received a bachelor’s degree in chemistry at the Virginia Polytechnic Institute and State University. In addition, he has received several professional distinctions certifications in Regulatory Affairs and Clinical Research.
“The addition of Mark to the Pharma Initiatives team expands our ability to assist biopharma leaders in achieving their strategic goals by overcoming operational hurdles,” said Gary Tyson, founder and Managing Partner of Pharma Initiatives. “Mark brings a wealth of consulting experience and operational leadership experience that will deliver results for our clients.”
About Pharma Initiatives
Pharma Initiatives is the leading management consultancy dedicated to business strategy in clinical research and medical affairs. PI has led hundreds of successful change management programs with biopharma organizations of all sizes. Using our proven approach to change management that ensures that change is understood and embraced, PI provides the expertise to rapidly analyze our client’s strategic situation, the creativity to identify unique solutions, and the discipline to work within challenging timelines. We deliver results for our clients, helping them drive innovation in organizational design, process optimization and technology adoption. Learn more at http://www.PharmaInitiatives.com.